Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYON3521 in c-MET Expressing Advanced Solid Tumors
NCT05323045Phase 1Completed
- Sponsor
- Byondis
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of BYON3521 in solid tumor, Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), ovarian cancer and 4 more, sponsored by Byondis. Primary endpoint: Incidence of Dose-Limiting Toxicities at 21 days. Started Mar 2022; status: completed.
02
Drugs
BYON3521
03
Conditions
solid tumorNonsquamous Non-Small Cell Lung Cancer (nsNSCLC)ovarian cancerendometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05323045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05323045.